FDA Panel Endorses GRAIL Galleri Cancer Screening Tool
The FDA advisory committee voted in favor of GRAIL's Galleri multi-cancer early detection test, moving it closer to official approval.
Stocks · News reference
Mizuho Maintains Neutral on GRAIL, Raises Price Target to $100
Mizuho analyst Bradley Bowers maintains GRAIL (NASDAQ:GRAL) with a Neutral and raises the price target from $65 to $100.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Trading Halt: Halt status updated at 7:00:00 AM ET: Quotation Resumption: News and Resumption Times
U.S. FDA Advisers Back Safety Of GRAIL's Galleri Multi-Cancer Screening Test; FDA Advisers Vote 6-4 That GRAIL's Galleri Is Effective For Proposed Use In Multi-Cancer Screening Test; Advisers Vote 7-2, With One Abstention, That Benefits Of GRAIL's Galleri Test Outweigh Risks For Proposed Use
https://www.fda.gov/media/194909/download